T ype 1 diabetes (T1D) 3 is a T cell-dependent autoimmune disease resulting in the destruction of the insulin-producing ␤ islet cells of Langerhans in the pancreas, leading to insulin deficiency (1, 2) . Studies in NOD mice show that the lag time between the establishment of insulitis and overt clinical T1D onset may result from a progressive loss of immunoregulatory mechanisms, which include naturally occurring CD4 ϩ regulatory T (nT reg ) cells (3) (4) (5) (6) . CD4 ϩ nT reg cells, constitutively expressing CD25 and the Foxp3 transcription factor (7-9), represent a major mechanism of peripheral self-tolerance, as their functional abrogation increases immunity to tumors, grafts, and pathogens and induces multiorgan-specific autoimmunity (10) . Defects in CD4 ϩ Foxp3 ϩ nT reg cell development or function promote T1D susceptibility (11, 12) and have been implicated as a central control point in T1D progression. T1D susceptibility is inherited through multiple genes, with a strong predisposition for those affecting T cell responses to ␤ islet cells (1) (2) (3) . Genomic mapping studies of congenic NOD strains, which harbor defined genetic intervals from T1D-resistant mice, have identified at least 20 insulin-dependent diabetes (Idd) regions that collectively contribute to disease susceptibility (13, 14) , although no single gene is both necessary and sufficient for complete disease protection. The Idd3 B6 locus, which maps to a 650-kb interval in the proximal region of chromosome 3, represents a major genetic determinant conferring T1D susceptibility (15) (16) (17) . NOD. B6 Idd3 mice, introgressed with the protective T1D-resistant Idd3 locus, show a marked resistance to reduced T1D onset (15, 18, 19) , while also affecting susceptibility to other organ-specific autoimmune diseases like experimental autoimmune encephalomyelitis and ovarian disease provoked by day 3 thymectomy (20, 21) . Interestingly, fine mapping and positional cloning studies of the Idd3 B6 locus have demonstrated that the Il2 gene is the primary candidate for Idd3-mediated protection in a model of CD8 ϩ T cell-induced T1D and a likely contributor to increased CD4 ϩ T reg cell activity in these mice (19, 22) . Although modest increases in their cellular frequency and in vitro function were observed, a detailed assessment of the impact of protective IL2 allelic variants (Idd3 B6 resistance allele) on the in vivo function of CD4 ϩ Foxp3 ϩ nT reg cells was not described (19, 22) .
A growing body of evidence strongly demonstrates that IL-2 is an important signal for CD4 ϩ Foxp3 ϩ nT reg cell development, function, homeostasis, and competitive fitness of nT reg cells in vivo. It is suggested that alterations in IL-2 signaling may attenuate nT reg cell function and provoke autoimmunity (23) . Furthermore, B7.1/B7.2 or CD28-deficient NOD mice have reduced CD4 ϩ Foxp3 ϩ nT reg cell numbers and manifest a more aggressive form of T1D than do control littermates (24, 25) , while systemic IL-2 neutralization provokes autoimmune neuropathy and accelerated T1D in NOD mice (26) . Moreover, T cells from prediabetic NOD 1 We acknowledge the support of the Canadian Institutes for Health Research (MOP 67211) and Canadian Diabetes Association (GA-3-05-1898-CP). A.A. and E.S. are recipients of fellowships from the McGill University Health Centre Research Institute (to A.A. and E.S.) and Canadian Institutes for Health Research training grant in neuroinflammation (to E.S.). C.A.P. is the recipient of the Canada Research Chair.
mice have reduced T cell proliferative and IL-2 production capabilities, hallmark features, which coincide with a skewing toward pathogenic, ␤-cell-specific Th1 cell effector function (27) . Recently, we have shown that Foxp3 ϩ nT reg cell function declines with age in NOD mice, despite stable cellular frequencies of Foxp3 ϩ nT reg cells, and that a possible loss in nT reg cell expansion in inflammatory sites may perturb the equilibrium between effector and nT reg cells within pancreatic sites, and amplifies local immune diabetogenic responses (12) . Interestingly, Tang et al. clearly demonstrated that administration of low-dose IL-2 promoted T reg cell survival and protected NOD mice from developing T1D (28) .
Presently, there is limited understanding in the regulation of T1D progression. Defining the mechanisms underlying the protective effects of T1D susceptibility gene variants, such as Idd3 B6 , is critical to understand how genetic variation may impinge natural checkpoints in T1D progression. Herein, we hypothesized that the protective IL2 allelic variants (Idd3 B6 locus) confer T1D protection by supporting CD4 ϩ nT reg cell function and expansion in vivo. We show that Idd3 B6 controls IL-2 secretion by islet-reactive CD4 ϩ effector T (T eff ) cells, favoring the cycling and function of CD4 ϩ Foxp3 ϩ nT reg cells locally in the pancreas, which in turn affords resistance to T1D. Thus, T1D genes may directly impinge the functional homeostasis of CD4 ϩ Foxp3 ϩ nT reg cells and, in turn, contribute to T1D susceptibility.
Materials and Methods

Mice
Mice strains were maintained in specific pathogen-free conditions at McGill University. NOD.TCR␣ Ϫ/Ϫ and BDC2.5 CD4 ϩ transgenic mice were a gift from Christophe Benoist (Harvard University, Boston, MA). BDC2.5 TCR transgenic NOD mice contain a monoclonal, ␤-islet-specific CD4 ϩ T cell repertoire (␣ 1 /␤ 4 ), thus providing a rapid, synchronous system for the analysis of Ag-specific T cell responses in vivo. NOD.B6 Idd3 congenic mice (line 1098) were obtained from Taconic Farms, and BDC.Idd3 mice were generated by in-house breeding.
Cell purification
CD4 ϩ , CD4 ϩ CD25 ϩ , and CD4 ϩ CD25 Ϫ T cell subsets were purified from lymph node (LN) or spleens using the autoMACS cell sorter (Miltenyi Biotec) or FACSAria flow cytometer (BD Biosciences), as described previously (29) .
Flow cytometry
Stainings were done with the following fluorochrome-conjugated or biotinylated mAbs: anti-CD4 (clone RM5), anti-CD25 (clone PC61), and anti-V␤4 (clone CTVB4) (eBioscience). Anti-Foxp3 (clone FJK-16s) and anti-Bcl-2 (clone 10C4) (eBioscience) intracellular staining was performed according to the manufacturer's protocol. Stained cells were acquired on a FACSCalibur (BD Biosciences) and analyzed with FlowJo software.
Ki-67 proliferation analysis
Pancreata were digested with collagenase type IV (Invitrogen) at 37°C, extensively washed in HBSS, followed by a 10-min incubation at 37°C in nonenzymatic dissociation solution (Invitrogen). Cells were stained with anti-Ki-67 (clone B56) (BD Biosciences), anti-CD4, anti-Foxp3, and anti-CD25 (eBioscience).
Adoptive transfers
FACS-purified CD4 ϩ CD25 Ϫ and CD4 ϩ CD25 ϩ T cells were transferred i.v., either alone or in combination, into NOD.TCR␣ Ϫ/Ϫ , NOD, or NOD. B6 Idd3 recipient mice (1:10 nT reg /T eff ratio; 2-3 ϫ 10 6 /mouse), as previously described (12) . In some cases, T cells were CFSE labeled (Invitrogen), and expansion of donor T cells was evaluated, as previously described (30) .
In vitro proliferation assays
Proliferation assays were performed by culturing CD4 ϩ T cells from NOD or BDC2.5 mice (5 ϫ 10 4 ) in 96-well flat bottom microtiter plates with irradiated, spleen cells (1-2 ϫ 10 5 ) and soluble anti-CD3 (1 g/ml) or BDC2.5 mimetope (RVRPLWVRME) (100 ng/ml) for 72 h at 37 o C in 5% CO 2 . Cell cultures were pulsed with 1Ci [ 3 H]TdR for the last 6 -12 h and analyzed as previously shown (29) . All experiments were repeated at least three times. Suppression assays were performed by culturing cell-sorted CD4 ϩ CD25 Ϫ BDC.Idd3 T cells with titrated numbers of highly purified BDC2.5 or BDC.Idd3 CD4 ϩ CD25 ϩ T reg cells, irradiated APCs, and BDC2. 5 mimetope (10 ng/ml) for 72 h. Cell cultures were pulsed with 1 Ci [ 3 H]TdR for the last 6 -12 h.
Intracellular cytokine production
Purified T cell subsets were stimulated 4 -5 h with PMA and ionomycin. In some instances, T cells were isolated from the pancreatic or distal LN of recipient mice following adoptive transfer, and were activated ex vivo overnight with bone marrow-derived dendritic cells (BMDC) and BDC2.5 mimetope, and treated with GolgiStop (BD Biosciences) for the last 2-3 h of culture. Intracellular cytokine staining (ICS) was performed using fluorochrome-conjugated anti-mouse mAb IL-2 (clone JES6-5H4), IFN-␥ (clone XMG1.2), IL-17 (clone eBio1787) (eBioscience), or appropriate isotype controls (BD Biosciences), as previously shown (12) .
Diagnosis of diabetes
Blood glycemia levels were determined every 2-3 days with Hemoglukotest kits (Roche Diagnostics), and T1D was diagnosed at values Ͼ300 mg/dl.
RT-PCR
Analysis of IL-2 gene expression in resting and activated CD4 ϩ T cell subsets was achieved by normalizing the IL-2 densitometric value with the intensity of the G3PDH amplicon for each sample, and reported as arbitrary IL-2/G3PDH ratios, as previously described (29) .
Statistical analysis
Results are expressed as means Ϯ SD. Analyses were performed with a Student's t test, except for diabetes incidences, where the Kaplan-Meier survival test was used. Values of p Ͻ 0.05 were considered significant.
Results
Resistance to the progression of T1D in NOD.B6 Idd3 congenic mice correlates with increased production of IL-2 by autoreactive CD4 ϩ T cells
We confirm that NOD.B6 Idd3 mice have a delayed onset and incidence of T1D compared with wild-type (WT) NOD mice (15) . Female NOD mice start to develop T1D by 14 wk of age and incidence reaches 85% by 28 wk. In contrast, only 10% of NOD. B6 Idd3 female mice were diabetic by 28 wk of age, with the earliest onset occurring at 25 wk of age ( Fig. 1A) , a finding consistent with the T1D protection seen in BDC.Idd3 mice (data not shown). We then assessed whether differences in the production of TNF-␣ and IFN-␥ by CD4 ϩ Th1 cells, important inflammatory mediators in this model, correlated with T1D protection in BDC.Idd3 mice. We show a significant, albeit modest, decrease in the percentage of CD4 ϩ V␤4 ϩ IFN-␥ ϩ T cells in peripheral LN (7.57 Ϯ 0.30% vs 5.83 Ϯ 0.26%; p ϭ 0.001), pancreatic LN (pancLN, 8.52 Ϯ 0.46% vs 7.14 Ϯ 0.20%; p ϭ 0.03), and in spleen (data not shown) of prediabetic BDC.Idd3 mice compared with BDC2.5 control mice following Ag-specific stimulation ( Fig. 1B) . Moreover, we also observe a substantial decrease in the frequency of CD4 ϩ V␤4 ϩ TNF-␣ ϩ T cells in peripheral LN (7.85 Ϯ 0.97% vs 5.09 Ϯ 0.17%; p ϭ 0.008), pancLN (7.51 Ϯ 0.43% vs 3.36 Ϯ 0.6%, p ϭ 0.002), and in spleen (data not shown) of BDC.Idd3 mice compared with BDC2.5 controls under similar stimulatory conditions (Fig. 1B) . The T1D resistance in NOD.B6 Idd3 mice also correlated with a significant reduction in CD4 ϩ T cell infiltration in the pancreas compared with WT NOD mice (1.04 Ϯ 0.3% vs 7.38 Ϯ 1.9%; p Յ 0.004) ( Fig. 1C) , an observation also made in BDC.Idd3 (data not shown). Thus, the T1D resistance in Idd3 congenic mice correlates with a significant reduction in the accumulation of T eff cells, particularly Th1 cells in lymphoid tissues or pancreas.
As the Il2 gene is the strongest and primary candidate for T1D protection in the Idd3 B6 locus, and it has been shown that the Il2 promoter from Idd3 B6 alleles possesses some sequence variation compared with the susceptible NOD allele (31, 32) , we wondered whether the Idd3 B6 interval increased IL-2 gene transcription and protein production in activated CD4 ϩ T cells of NOD.B6 Idd3 mice. To this end, CD4 ϩ T eff cells from prediabetic NOD and NOD.B6 Idd3 mice were activated with plate-bound anti-CD3, and IL-2 expression was assessed by RT-PCR in resting or TCR-stimulated conditions (Fig. 1D) . In contrast to unstimulated conditions, Il2 expression levels in NOD. B6 Idd3 CD4 ϩ T eff cells, albeit modestly greater than NOD T cells by 12 h of TCR engagement, were ϳ2-3-fold greater than their NOD CD4 ϩ CD25 Ϫ T cell counterparts by 24 -48 h post-TCR stimulation. This increased IL-2 expression in NOD.B6 Idd3 CD4 ϩ T cells also correlated with their augmented proliferation compared with NOD controls at 72 h poststimulation ( Fig. 1D and Fig. 2A ). To determine whether increased IL-2 transcription correlated with increased IL-2 production in Idd3 congenic mice, CD4 ϩ T eff cells from prediabetic NOD and NOD.B6 Idd3 or BDC2.5 and BDC.Idd3 mice were activated with PMA/ionomycin or BMDC in the presence of BDC2.5 mimetope, respectively, and IL-2 protein production was determined by FACS 24 h poststimulation. Our results show that activated T cells revealed an at least 2-fold increase in the fraction of cells producing IL-2 in Idd3 T cells compared with NOD control T cells without affecting the IL-2 mean fluorescence intensity in CD4 ϩ T cells of either genotype, suggesting that Idd3 B6 does not control the overall amount of IL-2 on a per cell basis ( Fig. 1E ). Thus, the protective Idd3 B6 allele causes an increase in the frequency of activated CD4 ϩ T cells producing IL-2, consistent with a recent study documenting similar increases in diabetogenic CD8 ϩ T cells from NOD.B6 Idd3 mice (22) .
Protective Idd3 B6 alleles augment CD4 ϩ Foxp3 ϩ nT reg cell function in vitro
Given the critical role of IL-2 in CD4 ϩ Foxp3 ϩ nT reg cell functions, we then hypothesized that the increased production of IL-2 by activated NOD.B6 Idd3 T cells may potentiate nT reg cell suppressive function and restrain the proliferative capacity of responding CD4 ϩ T cells. We first assessed the proliferation of CD4 ϩ T cells from NOD and NOD.B6 Idd3 WT mice or BDC2.5 and BDC. Idd3 CD4 ϩ TCR transgenic mice, whose monoclonal TCR repertoire is specific for an as of yet unknown pancreatic ␤-islet Ag Resistance to the progression of T1D in NOD.B6 Idd3 congenic mice correlates with increased production of IL-2 by autoreactive CD4 ϩ T cells. A, NOD.B6 Idd3 mice exhibit drastically reduced incidence and onset of diabetes relative to the WT NOD mice (n ϭ 20). B, Decreased frequency of IFN-␥ or TNF-␣ secreting CD4 ϩ T cells in BDC.Idd3 congenic mice. Lymph node cells were isolated from prediabetic, BDC2.5 or BDC.Idd3 mice (3-4 wk old) were cocultured with BMDC (4:1 ratio) and BDC2.5 mimetope (100 ng/ml), and the frequency of IFN-␥ and TNF-␣ producing CD4 ϩ V␤4 ϩ T cells was determined by ICS (n ϭ 5). Numbers represent the percentage of CD4 ϩ V␤4 ϩ IFN-␥ ϩ or CD4 ϩ V␤4 ϩ TNF-␣ ϩ cells. Results represent the means Ϯ SD. ‫,ء‬ p Յ 0.008 and †, p Ͻ 0.05 difference from control BDC2.5 IFN-␥ or TNF-␣ producing CD4 ϩ T cells. C, The Idd3 B6 locus drastically reduces the CD4 ϩ T cell infiltration in the pancreas of Idd3 congenic mice. Pancreata from 3-to 4-wkold NOD or NOD.B6 Idd3 mice were processed as described in Materials and Methods. The profiles (NOD. B6 Idd3 1.04 Ϯ 0.3% vs NOD 7.38 Ϯ 1.9%; p Յ 0.004) are representative of three (n ϭ 3) separate independent experiments. D, The Idd3 B6 locus leads to increased IL-2 gene transcription in CD4 ϩ T cells. CD4 ϩ CD25 Ϫ T cells were isolated from pooled LN of 3-4-wk-old NOD or NOD.B6 Idd3 mice and were activated under plate-bound anti-CD3 (5 g/ml) conditions. At various time points, total RNA was extracted and RT-PCR analysis of IL-2 relative to G3PDH gene expression was performed as described in Materials and Methods. E, Increased IL-2 protein secretion in activated CD4 ϩ T cells from NOD.B6 Idd3 or BDC.Idd3 mice. CD4 ϩ CD25 Ϫ T cells from pooled LN of 3-4-wk-old NOD and NOD.B6 Idd3 or BDC2.5 and BDC.Idd3 mice were stimulated with PMA/ionomycin or BMDC (4:1 ratio) and BDC2.5 mimetope (100 ng/ml), respectively, and ICS for IL-2 was performed. Data are representative of at least three separate experiments. Results represent the means Ϯ SD. p Ͻ 0.01, difference with NOD IL-2 producing CD4 ϩ CD25 Ϫ T cells after 24 h activation. (33) , activated with irradiated APC and soluble anti-CD3 or with the BDC2.5 mimetope, respectively. NOD or BDC2.5 CD4 ϩ T cells exhibited greater proliferation relative to total NOD.B6 Idd3 and BDC.Idd3 CD4 ϩ T cells under similar stimulatory conditions ( Fig. 2A ). Consistently, depletion of NOD.B6 Idd3 or BDC.Idd3 CD4 ϩ CD25 ϩ T cells resulted in a more significant increase in proliferation than similar treatments in T cells from NOD or BDC2. 5 mice (data not shown).
To address whether the reduced proliferation observed in Idd3 B6 CD4 ϩ T cells was a consequence of an increased CD4 ϩ Foxp3 ϩ nT reg cell pool within activated CD4 ϩ T cells, we determined the frequency of dividing CD4 ϩ Foxp3 ϩ nT reg cells within the total CD4 ϩ T cell pool subsequent to anti-CD3 or mimetope stimulation by CFSE dilution analysis (Fig. 2B ). Our results show no difference in the percentage of CD4 ϩ Foxp3 ϩ nT reg cells between un-activated CD4 ϩ T cells from NOD and NOD.B6 Idd3 or BDC2.5 and BDC.Idd3 (Fig. 2B ). However, activated CD4 ϩ T cells from NOD.B6 Idd3 and BDC.Idd3 revealed a significantly increased proportion of CD4 ϩ Foxp3 ϩ nT reg cells at 72 h postactivation when compared with NOD and BDC2.5 T cells, consistent with the reduced proliferation of CD4 ϩ T eff cells (Fig. 2, A and B) . Notably, the higher percentage of CD4 ϩ Foxp3 ϩ nT reg cells within the activated CD4 ϩ T cell pool from Idd3 B6 congenic mice correlated with increased proliferation (11.4 Ϯ 1.2 vs 7.7 Ϯ 0.6; p Յ 0.009) ( Fig. 2C ) and increased numbers (data not shown) of CD4 ϩ Foxp3 ϩ nT reg cells, suggesting that Idd3 B6 CD4 ϩ Foxp3 ϩ nT reg cells are intrinsically more potent in their function than are WT NOD controls.
We then performed in vitro suppression assays to directly assess whether enhanced CD4 ϩ CD25 ϩ nT reg cell-mediated suppression is affected in BDC.Idd3 congenic mice. Our results show that CD4 ϩ CD25 ϩ nT reg cells from BDC.Idd3 mice were more efficient than BDC2.5 controls in suppressing anti-CD3-induced T cell proliferation at all nT reg /responder T cell ratios examined, a finding consistent with CD4 ϩ CD25 ϩ nT reg cells from NOD.B6 mice ( Fig.  2D and data not shown). Overall, these findings demonstrate the ability of the protective Idd3 B6 allele to favor the function of CD4 ϩ Foxp3 ϩ nT reg cells, which in turn dampen the proliferation of activated CD4 ϩ T eff cells in vitro more efficiently than in their BDC2. 5 counterparts.
Expansion of islet-reactive CD4 ϩ T cells is dampened in NOD.B6 Idd3 mice
We sought to assess the impact of the protective Idd3 B6 locus on diabetogenic CD4 ϩ T eff cell activation and expansion in vivo. To this end, CD4 ϩ CD25 Ϫ T eff cells from BDC2.5 or BDC.Idd3 mice were CFSE labeled, adoptively transferred into NOD or NOD.B6 Idd3 recipients, and proliferation was monitored by CFSE dilution. BDC2.5 and BDC.Idd3 T eff cells proliferated and accumulated abundantly in the pancLN of NOD and NOD.B6 Idd3 recipient mice (Fig. 3, A and B) , but not in other peripheral LN (data not shown), confirming that T cell priming was ␤-islet Ag specific. Our results also reveal a more significant reduction in the Agdriven proliferation and total accumulation of both BDC2.5 and BDC.Idd3 T eff cells in the pancLN of NOD.B6 Idd3 mice compared with NOD controls (Fig. 3, A and B) . Interestingly, BDC. Idd3 T eff cell Ag-induced proliferation was as efficient as that of BDC2.5 T eff cells in NOD recipient mice. This suggests that priming of diabetogenic T cells was not affected by the action of the Idd3 B6 allele in donor T eff cells. Instead, suppression of islet-reactive CD4 ϩ T eff cell priming is seemingly dependent on the presence of the protective Idd3 B6 allele in recipient mice (Fig. 3, A and  B) . Thus, the protective Idd3 B6 allele promotes a more suppressive environment, which impedes the activation and accumulation of Ag-specific, diabetogenic CD4 ϩ T eff cells in vivo.
To exclude the possibility that DC from Idd3 congenic mice might be more tolerogenic in nature and may be, on their own, responsible for the suppressive environment in these mice, we activated BDC2.5 CD4 ϩ T cells in vitro with CD11c high MHC class II ϩ dendritic cells (DC) purified from draining pancLN or spleen of BDC2.5 or BDC.Idd3 mice, and in the presence of BDC2.5 mimetope. Our results show that splenic or pancLN DC from Idd3 congenic mice were as potent in inducing Ag-specific T cell proliferation as DC from NOD controls ( Fig. 3C ), suggesting that the suppressive environment conferred by the protective Idd3 B6 locus is independent of more tolerogenic DC in Idd3 congenic mice. CD4 ϩ T cells (5 ϫ 10 4 ) were isolated from LN of 3-4-wk-old WT or NOD.B6 Idd3 congenic mice and activated with irradiated splenocytes (2 ϫ 10 5 ) and anti-CD3 (1 g/ml). CD4 ϩ T cells from BDC2.5 and BDC. Idd3 mice (1 ϫ 10 5 ) were activated in the presence of LPS-matured BMDC (2.5 ϫ 10 4 ) pulsed with the BDC2.5 mimetope (300 ng/ml). In all instances, proliferation was assessed by thymidine incorporation at 72 h postactivation. Results represent the means Ϯ SD. ‫,ء‬ p Ͻ 0.01 difference with NOD or BDC2.5 T eff cell proliferation. B, Decreased proliferation of T cells in NOD.B6 Idd3 and BDC.Idd3 congenic mice relative to WT NOD and BDC2.5, respectively, correlates with an augmented proportion of CD4 ϩ Foxp3 ϩ nT reg cells in activated CD4 ϩ T cells. CD4 ϩ T cells (1 ϫ 10 5 ) from LN of NOD and NOD.B6 Idd3 or BDC2.5 and BDC.Idd3 mice were activated with irradiated splenocytes (4 ϫ 10 5 ) and anti-CD3 (1 g/ ml) or BDC2.5 mimetope-pulsed (300 ng/ml) BMDC, respectively. Results represent the means Ϯ SD. ‫,ء‬ p Ͻ 0.01 difference with control NOD or BDC2.5 Foxp3 frequencies 72 h postactivation. C, CFSE-labeled BDC2.5 and BDC.Idd3 CD4 ϩ CD25 ϩ/Ϫ T cells were activated for 72 h with mimetope-pulsed (100 ng/ml) BMDC, and the frequency of dividing CD4 ϩ V␤4 ϩ Foxp3 ϩ T cells was assessed by FACS. p Ͻ 0.009 difference with BDC2.5 dividing T reg cells. D, CD4 ϩ CD25 ϩ nT reg cells from BDC. Idd3 are more suppressive in vitro than are their BDC2.5 control littermates. CD4 ϩ CD25 Ϫ responder T cells from BDC.Idd3 congenic mice (5 ϫ 10 4 ) were stimulated with anti-CD3 (1 g/ml) and irradiated spleen cells (2 ϫ 10 5 ) in the presence or absence of titrated numbers of CD4 ϩ CD25 ϩ nT reg cells from BDC2.5 or BDC.Idd3 mice. Data are representative of three separate experiments. Results represent the means Ϯ SD. ‫,ء‬ p Ͻ 0.02 and †, p Ͻ 0.04 difference with WT control BDC2.5 T eff cell proliferation.
The differentiation of diabetogenic, IL-17-producing CD4 ϩ T cells in pancLN is suppressed in NOD.B6 Idd3 congenic mice
Since the proliferative capacity of autoreactive CD4 ϩ T eff cells was suppressed more efficiently in NOD.B6 Idd3 congenic mice than in control NOD mice, we wondered whether the differentiation of diabetogenic CD4 ϩ T cell pool would also be affected by protective Idd3 alleles. While inflammatory cytokines produced by Th1 cells and DC, like IFN-␥, IL-12, and TNF-␣, are important mediators of ␤-islet destruction and play a pivotal role in the development of the insulitic lesions (34) , recent studies show that IL-17-producing CD4 ϩ T (Th17) cells are important mediators of the pathogenesis in various autoimmune disorders (35, 36) . Moreover, IL-17 mRNA transcripts have been shown to increase with the onset and severity of T1D (35, 36) . We hypothesized that these important inflammatory mediators were suppressed by the presence of the protective Idd3 B6 allele. To this end, BDC2.5 or BDC. Idd3 CD4 ϩ T cells were injected into NOD or NOD.B6 Idd3 recipients, and 4 days post-transfer, distal and pancLN cells were activated with mimetope-pulsed DC ex vivo and the production of IL-17 in T cells was assessed by ICS. Our results show that when BDC2.5 CD4 ϩ T cells were transferred into WT NOD recipients, a 6.5-fold enhancement in the frequency IL-17 producing CD4 ϩ T cells was observed (10.67 Ϯ 4.2% vs 1.61 Ϯ 0.5%; p Յ 0.02) compared with BDC2.5 or BDC.Idd3 CD4 ϩ T cells transferred into NOD.B6 Idd3 recipient mice. This suggested that the presence of the Idd3 B6 locus in either donor T cells or recipient mice was sufficient to severely hamper the differentiation of IL-17 producing CD4 ϩ T cells (Fig. 4) . Interestingly, IL-17 production was markedly hindered when the protective Idd3 B6 allele was present either exogenously within the donor cells or endogenously within the recipient animals ( Fig. 4) . These findings strongly suggest that the Idd3 B6 locus impacts the diabetogenic T cell pool by hindering its differentiation.
The Idd3 B6 locus drives CD4 ϩ Foxp3 ϩ nT reg cell suppressive function and T1D protection
We then sought to directly determine whether CD4 ϩ Foxp3 ϩ nT reg cells from Idd3 B6 congenic mice were intrinsically better inhibitors of diabetogenic T cells and T1D in vivo. To this end, we transferred CD4 ϩ CD25 Ϫ T eff cells from BDC2.5 or BDC.Idd3 mice into NOD.TCR␣ Ϫ/Ϫ recipients either alone or in combination with BDC2.5 or BDC.Idd3 CD4 ϩ CD25 ϩ nT reg cells at physiological 1:10 T reg /T eff cell ratios, and the onset of diabetes was monitored. Recipient mice transferred with BDC2.5 or BDC.Idd3 T eff cells alone developed T1D simultaneously between days 11 and 14 and with similar incidence, suggesting that the Idd3 B6 allele did not affect the diabetogenic potential of T eff cells in vivo (data not shown). Similarly, BDC2.5 and BDC.Idd3 T eff cells accumulated with similar frequencies in the pancreas of recipient mice, further confirming that the Idd3 B6 allele does not directly impede the influx of islet-reactive CD4 ϩ T eff cells in vivo (data not shown). Interestingly, 80% of the recipients receiving BDC2.5 T eff and T reg cells developed diabetes by day 20 post-transfer, demonstrating that WT BDC2.5 T reg cells are unable to maintain long-term selftolerance ( Fig. 5A) . Intriguingly, BDC2.5 CD4 ϩ CD25 ϩ T reg cells were capable of significantly reducing T1D incidence (40%) when cotransferred with BDC.Idd3 T eff cells, suggesting that the presence of the Idd3 B6 allele in islet-reactive CD4 ϩ T eff cells is capable of potentiating the function of BDC2.5 CD4 ϩ T reg cells in vivo. In stark contrast, NOD.TCR␣ Ϫ/Ϫ recipient mice receiving BDC.Idd3 CD4 ϩ CD25 ϩ T reg cell populations, irrespective of the genotype of the T eff cell group, remained completely T1D-free for up to 20 days post-transfer, suggesting that BDC.Idd3 CD4 ϩ CD25 ϩ T reg cells are more efficient at controlling the onset of T1D (Fig. 5A) . Thus, these results show that Idd3 B6 allelic variants drive the development of intrinsically more potent CD4 ϩ Foxp3 ϩ nT reg cells, which, in turn, impact disease progression and resistance to T1D.
Studies in various mouse models of disease indicate that nT reg cells can localize in sites of inflammation to mediate their protective effect (30, (37) (38) (39) . Given the increased suppression of T1D in mice receiving BDC.Idd3 nT reg cells, we then asked whether this protection was due to increased accumulation of CD4 ϩ Foxp3 ϩ nT reg cells in the pancreas. To this end, nondiabetic NOD. TCR␣ Ϫ/Ϫ mice receiving CD4 ϩ T eff and nT reg cells from BDC2.5 or BDC.Idd3 donors were sacrificed on day 15 post-transfer, and the cellular frequency of nT reg and T eff cells was analyzed in the pancreas and various lymphoid organs. Our results show that no significant differences are detected in the overall frequencies of FIGURE 3. The expansion and accumulation of islet-reactive CD4 ϩ T cells is dampened in NOD.B6 Idd3 mice. CFSE-labeled CD4 ϩ CD25 Ϫ T cells (3 ϫ 10 6 ) from BDC2.5 or BDC.Idd3 mice were adoptively transferred into NOD or NOD.B6 Idd3 recipients. The pancLN of recipient mice were harvested on day 4 post-transfer, and the proliferative capacity (A) and absolute numbers (B) of donor CD4 ϩ V␤4 ϩ T cells were determined in recipient mice (n ϭ 3-4 mice/group). Similar results were obtained in three independent experiments. Results represent the mean Ϯ SD. ‫,ء‬ p Ͻ 0.02 difference between recipients receiving BDC2.5 T eff cells or recipients receiving BDC.Idd3 T eff cells. C, DC from draining pancreatic sites do not drive the Idd3-mediated effect on T eff cell expansion. To examine the impact of DC on the proliferative capacity of CD4 ϩ T cells, CD11c high MHC II ϩ DC were purified from draining pancLN and spleen of 3-to 4-wk-old BDC2.5 or BDC.Idd3 mice and plated at a 1:4 ratio with highly purified BDC2.5 CD4 ϩ T cells in the presence of BDC2.5 mimetope (100 ng/ml) for 72 h. Proliferation was assessed by thymidine incorporation. No significance (n.s.) was observed between groups.
CD4 ϩ V␤4 ϩ T cells in the pancLN and pancreas of recipient mice regardless of T eff and nT reg cell origin, although frequencies of CD4 ϩ Foxp3 Ϫ T eff cells in the pancLN and pancreas of recipient mice were significantly reduced in the presence of BDC.Idd3 nT reg cells (data not shown). Strikingly, mice receiving BDC.Idd3 CD4 ϩ CD25 ϩ nT reg cells showed increased frequencies of CD4 ϩ Foxp3 ϩ nT reg cells in the pancLN and pancreas compared with mice receiving BDC2.5 CD4 ϩ Foxp3 ϩ nT reg cells (Fig. 5B ). Interestingly, a significantly greater frequency of intrapancreatic CD4 ϩ Foxp3 ϩ nT reg cells was observed in cotransfers with BDC.Idd3 T eff cells compared with BDC2.5 T eff cells, indicating that Idd3 B6 allelic variants in diabetogenic T cells on their own may not be sufficient to promote CD4 ϩ Foxp3 ϩ nT reg cell activity and may act in a nT reg cell-intrinsic fashion (Fig. 5B) . Thus, the decreased accumulation of CD4 ϩ Foxp3 ϩ nT reg cells in the pancreas of BDC2.5 mice may suggest that they may be impaired in their ability to delay disease progression due to reduced functional capacities in situ.
We next determined whether this preferential accumulation of BDC.Idd3 CD4 ϩ Foxp3 ϩ nT reg cells in the pancreas also occurred in nonlymphopenic BDC2.5 and BDC.Idd3 mice. While the percentage of CD4 ϩ Foxp3 ϩ nT reg cells in nondraining lymphoid sites in BDC2.5 and BDC.Idd3 mice did not differ, BDC.Idd3 mice show significantly higher frequencies of nT reg cells in the pancreas compared with BDC2.5 mice (28.8Ϯ 11.1% vs 11.4 Ϯ 3.9%; p Ͻ CD4 ϩ CD25 Ϫ T eff cells (5 ϫ 10 5 ) in the presence or absence (data not shown) of BDC2.5 or BDC.Idd3 CD4 ϩ CD25 ϩ (5 ϫ 10 4 ) nT reg cells from peripheral LN of 6-to 8-wk-old donor mice. Blood glucose levels in recipient mice (n ϭ 7 recipients/group) were monitored for diabetes incidence every 48 h posttransfer. Results represent the means Ϯ SD. p Ͻ 0.0001 difference between control NOD.TCR␣ Ϫ/Ϫ recipient mice receiving BDC2.5 T eff /BDC2.5 nT reg cells and those receiving BDC.Idd3 T eff / BDC.Idd3 nT reg cells. p Ͻ 0.05 difference in diabetes onset between control NOD.TCR␣ Ϫ/Ϫ recipient mice receiving BDC2.5 T eff /BDC2.5 nT reg cells and those receiving BDC.Idd3 T eff /BDC2.5 nT reg cells. B, Increased accumulation of CD4 ϩ Foxp3 ϩ nT reg cells in pancreatic sites of mice receiving BDC2.5 or BDC.Idd3 nT reg cells. NOD.TCR␣ Ϫ/Ϫ recipient mice (n ϭ 2-4 mice/group) were adoptively transferred as in (A), and on day 16 posttransfer, mice from each group were sacrificed, pancLN and pancreas were harvested, and the cellular frequency of islet-specific Foxp3 ϩ nT reg cells within the CD4 ϩ V␤4 ϩ T cell compartment was determined by FACS. ‫,ء‬ p Ͻ 0.01 and †, p Ͻ 0.05 difference with control NOD.TCR␣ Ϫ/Ϫ mice receiving BDC2.5 or BDC.Idd3 T reg cells along with BDC2.5 T eff or those receiving BDC2.5 or BDC.Idd3 T reg cells along with BDC.Idd3 T eff cells. C, Total frequency of islet-specific CD4 ϩ V␤4 ϩ T cells (left panel) and CD4 ϩ V␤4 ϩ Foxp3 ϩ nT reg cells (right panel) was determined in the pan-cLN and pancreas of 3-to 4-wk-old BDC2.5 and BDC.Idd3 mice (n ϭ 10). Data are representative of the compilation of several independent experiments. Results represent the means Ϯ SD. ‫ء‬ p ϭ 0.0005 difference with control BDC2.5 mice. 0.0002) ( Fig. 5C, right panel) and this correlated with a significantly reduced percentage of islet-specific CD4 ϩ T eff cells in the pancreas (19.0 Ϯ 9.9% vs 32.3 Ϯ 7.9%; p Ͻ 0.005) and, albeit to a lesser extent, in the pancLN (52.7 Ϯ 7.8% vs 67.8 Ϯ 8.2%; p Ͻ 0.005) (Fig. 5C, left panel) . Overall, our results show that protective Idd3 B6 alleles favor high frequencies of nT reg cells in the target organ, which suppress the accumulation of islet-specific CD4 ϩ T eff cells and prevent the induction of T1D.
The Idd3 B6 allele does not enhance resistance to apoptosis in T reg cells
We show that T1D protection in BDC.Idd3 mice correlates directly with an increased proportion of CD4 ϩ Foxp3 ϩ nT reg cells in the target organ of prediabetic mice. Recently, we showed that T1D is not attributed to quantitative fluctuations in CD4 ϩ Foxp3 ϩ T reg cells but more so to a temporal loss in the capacity of CD4 ϩ Foxp3 ϩ T reg cells to expand in pancreatic sites, which in turn unleashes the diabetogenic potential of T eff cells (12) . We hypothesized that Idd3 B6 resistance alleles augment the homeostasis of nT reg cells locally in the pancreas, correcting for the homeostatic "defect" in the BDC2.5, and consequently suppressing the function of diabetogenic T cells in situ. The Idd3 B6 -mediated quantitative change in T reg cells may result from a heightened resistance to apoptosis, consequently leading to their accumulation in pancreatic sites. To this end, we examined by FACS various lymphoid organs and the pancreas of prediabetic NOD and NOD.B6 Idd3 or BDC2. 5 and BDC.Idd3 mice for the expression of Bcl-2, a critical mediator in the anti-apoptotic pathway. Our results show that neither the frequency of Bcl-2-positive CD4 ϩ Foxp3 ϩ nT reg cells nor the amount of Bcl-2 produced in CD4 ϩ Foxp3 ϩ nT reg cells varied between NOD and NOD.B6 Idd3 mice (Fig. 6, left panel) or BDC2.5 and BDC.Idd3 mice (Fig. 6, right panel) . Hence, the protective Idd3 B6 alleles do not modulate T reg cell functions by mediating their resistance to apoptosis.
The Idd3 B6 locus potentiates T reg cell proliferation in vivo
Since the increased proportion of T reg cells in the pancreas of protected BDC.Idd3 mice could not be attributed to prolonged survival, we hypothesized that an enhanced local expansion of T reg cells could explain the protective phenotype observed in animals containing the Idd3 B6 interval. To evaluate the impact of the Idd3 B6 locus on T reg cell expansion in draining pancLN, CFSElabeled BDC2.5 or BDC.Idd3 CD4 ϩ T cells were transferred into NOD or NOD.Idd3 recipients and proliferation was monitored. The greatest nT reg cell proliferation was observed when both the donor cells and recipient animals originated from Idd3 B6 congenic mice (41.62 Ϯ 10.1%), suggesting that both T reg cell-intrinsic and -extrinsic factors cooperated to yield enhanced proliferative capacity (Fig. 7A) . Interestingly, BDC.Idd3 CD4 ϩ V␤4 ϩ Foxp3 ϩ T reg cells accumulated in greater numbers in draining pancreatic sites, irrespective of the genotype of the recipient animals, confirming that the Idd3 B6 locus drives T reg cell expansion and promotes their accumulation in pancLN (Fig. 7B) . The presence of donor T reg cells in this system did not impede the activation of the diabetogenic T cell pool, as T eff cells from both genotypes exhibited similar proliferative profiles, irrespective of the origin of the recipient animal (data not shown). Interestingly, the accumulation of CD4 ϩ V␤4 ϩ Foxp3 Ϫ T eff cells was drastically reduced in NOD.B6 Idd3 recipients irrespective of the genotype of the donor T cells (Fig. 7C) , demonstrating that the NOD.B6 Idd3 environment is tolerogenic and impedes the expansion of diabetogenic T eff cells. Thus, these data highlight the importance of the Idd3 B6 locus in promoting T reg cell proliferation and restraining the expansion of diabetogenic T eff cells.
IL-2 allelic variants promote the cycling of CD4 ϩ Foxp3 ϩ nT reg cells directly in the pancreas
Since a greater proportion of T reg cells accumulated and proliferated in draining pancreatic sites of NOD.B6 Idd3 animals, we wondered whether the observed increased frequency of Idd3 T reg cells within the target organ ( Fig. 5C, right panel) was attributed to more efficient expansion in situ. To examine this possibility, we determined the cellular frequency of cycling CD4 ϩ Foxp3 ϩ T cells, as determined by the Ki-67 proliferation marker, in the spleen, nondraining mesenteric LN, pancLN, and pancreas of BDC2. 5 and BDC.Idd3 mice. Our results show a marked decrease in the proportion of cycling CD4 ϩ Foxp3 Ϫ T eff cells within the pancreas of BDC.Idd3 relative to WT BDC2.5 mice (17.4 Ϯ 4.0% vs 28.0 Ϯ 3.8%; p Ͻ 0.00001) (Fig. 8A) , and similar cycling differences could not be detected in spleen and distal LN, suggesting that T1D protection in BDC.Idd3 mice correlates directly with the increased proportion of CD4 ϩ Foxp3 ϩ nT reg cells in the target organ. Additionally, although no significant differences were observed in non-draining and draining lymphoid sites between genotypes, the proportion of cycling nT reg cells was markedly enhanced within the pancreas of BDC.Idd3 mice relative to WT BDC2.5 mice, and correlated with the frequency of CD25-expressing cycling nT reg cells (13.4 Ϯ 3.1% vs 6.5 Ϯ 2.5%; p Ͻ 0.0001) (Fig. 8B ). This suggests that an increase in IL-2 in the inflammatory milieu, generated by the diabetogenic T eff cell pool, drives the up-regulation of CD25, potentiating T reg cell suppressive functions, a finding consistent with the observed local expansion of CD4 ϩ Foxp3 ϩ nT reg cells within inflammatory sites seen in other mouse models (10, 37, 38, 41, 42) . More importantly, the decline in cycling CD4 ϩ Foxp3 Ϫ T eff cells in BDC.Idd3 mice correlates directly with an increased proportion of cycling CD4 ϩ Foxp3 ϩ nT reg cells (12.0 Ϯ 0.8% vs 4.4 Ϯ 1.9%; p ϭ 1.1 ϫ 10 Ϫ8 ), suggesting that the proliferative potential of nT reg cells correlates directly with their functional potency, and is strongly indicative that nT reg cells are actively suppressing autoreactive CD4 ϩ Foxp3 Ϫ T eff cells within the target organ ( Fig. 8 ). Collectively, our data strongly suggest that a regulatory feedback loop initiated by IL-2-producing selfreactive Idd3 B6 CD4 ϩ T cells favors the preferential expansion and function of CD4 ϩ Foxp3 ϩ nT reg cells within the target organ, in turn increasing the T reg /T eff cell ratio and tipping the balance to self-tolerance.
Discussion
CD4 ϩ Foxp3 ϩ nT reg cells have been implicated as a central control point in the pathogenesis of T1D in NOD mice (30, 43) . T1D resistance also correlates with the expansion of CD4 ϩ CD25 ϩ T cells within pancLN and insulitic lesions, and with a consequential decrease in the priming, expansion, or differentiation of T eff cells in these sites (30, 41, 44, 45) . Developmental or functional defects of CD4 ϩ Foxp3 ϩ nT reg cells in autoimmune-prone hosts may represent a major predisposition factor for spontaneous T1D (46, 48) .
Fine mapping studies have established Il2 as the primary genetic determinant of disease protection operative in the Idd3 B6 locus (22, 31) . Considering the critical role of IL-2 in nT reg cell functions, we hypothesized that Idd3 B6 protective alleles impart potent resistance to T1D by potentiating nT reg cell-mediated regulation of diabetogenic T cells. We found that the protective Idd3 B6 allele, relative to the NOD allele, augments the amount of IL-2 mRNA and protein produced by diabetogenic CD4 ϩ T eff cells and affords resistance to spontaneous and CD4 ϩ T cell-induced T1D. While the frequency of CD4 ϩ Foxp3 ϩ nT reg cells is not affected, and their functional potency is increased in Idd3 B6 congenic mice, we make the novel finding that Idd3 B6 protective alleles primarily favor T1D disease resistance by heightening the cycling and function of CD4 ϩ Foxp3 ϩ nT reg cells locally within the inflammatory environment of the pancreas. Collectively, we show that the T1D-protective Idd3 B6 allele variants dictate the amount of IL-2 production by diabetogenic CD4 ϩ T eff cells, which initiates a regulatory feedback loop driving the functional homeostasis of CD4 ϩ Foxp3 ϩ nT reg cells in the target organ.
IL-2 is now viewed as an important signal for the development, function, and competitive fitness of nT reg cells in vivo (23, 26) . As CD4 ϩ Foxp3 ϩ nT reg cells fail to make IL-2, their primary source of IL-2 in vivo is likely CD4 ϩ T eff cells (29, 50, 51) . Indeed, mice deficient for B7/CD28, CD40/CD40L, IL-2, IL-2R␣/␤, or STAT5A/B have drastically reduced nT reg cell numbers and suffer from severe autoimmunity (24, 25, (52) (53) (54) (55) (56) (57) . Consistently, in vivo neutralization of IL-2 in NOD mice actually precipitates the onset and incidence of T1D (26) . Interestingly, NOD T cells respond normally to TCR activation until 4 wk of age, at which point they become anergic and sustain a drastic reduction in IL-2 production, coinciding with the onset of insulitis (3). This reduced IL-2 expression and activity in NOD mice may abrogate nT reg cell function and subsequently enable diabetogenic T cells to transition from insulitis (checkpoint 1) to overt T1D (checkpoint 2). Thus, temporal alterations in IL-2 expression in the prediabetic phase of NOD mice may influence nT reg cell development and ultimately affect T1D onset (12, 23, 26) .
Our results show that the protective effect of Idd3 B6 requires the presence of CD4 ϩ Foxp3 ϩ nT reg cells, since depletion of CD4 ϩ CD25 ϩ nT reg cells (90% of Foxp3 ϩ nT reg cells) from CD4 ϩ T cells unleashes the diabetogenic potential of BDC.Idd3 T eff cells in vivo. Although our data show that the Idd3 environment conditions T reg cells to be more suppressive, the protection conferred by the Idd3 B6 allele is neither dominant nor recessive but more so dose dependent in nature (15, 22) . In this instance, the Idd3 B6 allele would likely result in higher IL-2 levels, particularly in the local environment of inflammation, which in turn would affect nT reg cell homeostasis and function to assure disease protection. Interestingly, recent evidence has demonstrated that IL-2 is a potent inhibitor of Th17 cell differentiation in vitro and in vivo (58) . Our data would also suggest that the increased production of IL-2 by T cells from Idd3 B6 mice might promote protection to T1D by hindering Th17 cells while simultaneously promoting CD4 ϩ Foxp3 ϩ T reg cells. Thus, our model would suggest that the presence of protective Idd3 B6 alleles permits diabetogenic CD4 ϩ T cells to produce sufficient IL-2 to optimally promote the expansion and function of CD4 ϩ Foxp3 ϩ nT reg cells in the pancLN and pancreas, and in turn blocking the diabetogenic process in the target organ. Consistently, administration of low-dose IL-2 promoted T reg cell survival and protected NOD mice from developing T1D (28) .
Studies have shown that the "susceptible" and "resistant" IL-2 differ in their N-terminal sequence, correlating with putative, differential glycosylation states, suggesting that IL-2 variants may be functionally distinct, potentially affecting the synthetic rate, protein folding/half-life, binding affinity, or signaling of IL-2 (32). Yamanouchi et al. recently demonstrated that several single nucleotide polymorphisms within the 5Ј region of the NOD haplotype of Il2 promoter collectively influence the competency of activated CD8 ϩ T cells to initiate IL-2 transcription or secrete IL-2 protein in activated self-reactive T cells (22) . This increased IL-2 expression by the Idd3 B6 allele in activated T cells may be related to improved assembly/activation of the transcription machinery during T cell activation (59, 60) , in turn enabling more efficient IL-2 transcription or secretion in T cells with the downstream effect of increasing the cellular frequency of IL-2 secreting CD4 ϩ T cells in a given immune response. More importantly, the sole presence of Idd3 B6 protective alleles in diabetogenic CD4 ϩ T eff cells is able to partially correct the "defective fitness" of CD4 ϩ Foxp3 ϩ nT reg cells in NOD hosts (Fig. 5A) , indicating that Idd3 B6 allelic variants in diabetogenic T cells are important contributors in selftolerance mechanisms. These results do not exclude a possible CD4 ϩ nT reg cell-intrinsic role for protective Idd3 alleles.
The capacity of nT reg cells to localize directly within inflamed tissues to dampen immune responses has been shown in various models of infectious disease, inflammatory bowel disease, and tumors (37, 39, 40) . Similarly, CD4 ϩ Foxp3 ϩ nT reg cells block the diabetogenic process, in part, by localizing within insulitic lesions, where they suppress the function of T eff cells (12, 30, 45, 61) . We show that nT reg cells from BDC.Idd3 mice preferentially expand within the pancreas of T1D-protected mice, where they control the effector functions of infiltrating diabetogenic CD4 ϩ Foxp3 Ϫ T cells. This would suggest that the loss of Ag-driven homing, activation, or expansion of nT reg cells in pancreatic sites may represent an essential checkpoint in the T1D progression, and that the protective Idd3 B6 alleles correct for this defect in NOD.B6 Idd3 mice. It is unknown whether Idd3 B6 engages unique transcriptomes in infiltrating nT reg cells, particularly with regard to genes affecting metabolism, cell cycle, homing, and survival of nT reg cells.
In conclusion, we link the T1D-protective affect of Idd3 B6 with a more potent CD4 ϩ Foxp3 ϩ nT reg cell compartment, particularly with regard to its ability to promote regulatory function in the local inflammatory environment of the pancreas. Our results are potentially relevant to human T1D considering that some studies have suggested a reduction of nT reg cell number and/or function in individuals with T1D (62). In human T1D, the genes for CTLA-4, insulin, and PTPN22 (protein tyrosine phosphatase, nonreceptor type 22) map to T1D susceptibility, and although an association with IL2 in human T1D has not been made, recent studies identified two single nucleotide polymorphisms in IL2ra/CD25, which correlate with T1D susceptibility in humans (63) (64) (65) (66) . Thus, the control of organ-specific autoimmunity is critically dependent on the dominant regulation of self-reactive T cells, and that in genetically susceptible subjects with a defective CD4 ϩ Foxp3 ϩ nT reg cell compartment, an increase in IL-2R signaling may diminish T1D risk. This study illustrates that some T1D susceptibility genes may alter the balance between pathogenic and nT reg cell populations and ultimately contribute to T1D pathogenesis.
